Literature DB >> 20199764

Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.

F M Russell1, P V Licciardi, A Balloch, V Biaukula, L Tikoduadua, J R Carapetis, J Nelson, A W J Jenney, L Waqatakirewa, S Colquhoun, Y B Cheung, M L K Tang, E K Mulholland.   

Abstract

Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p<0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20199764      PMCID： PMC2857918          DOI： 10.1016/j.vaccine.2010.02.065

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  40 in total

1.  A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers.

Authors:  M D Blum; R Dagan; P M Mendelman; V Pinsk; M Giordani; S Li; N Bohidar; T B McNeely
Journal:  Vaccine       Date:  2000-05-08       Impact factor: 3.641

2.  Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a haemophilus influenzae type B conjugate vaccine in United Kingdom infants.

Authors:  S Choo; L Seymour; R Morris; S Quataert; S Lockhart; K Cartwright; A Finn
Journal:  Pediatr Infect Dis J       Date:  2000-09       Impact factor: 2.129

3.  Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.

Authors:  J MacLennan; S Obaro; J Deeks; D Lake; C Elie; G Carlone; E R Moxon; B Greenwood
Journal:  J Infect Dis       Date:  2000-11-15       Impact factor: 5.226

4.  Effects of pneumococcal vaccination on tonsillo-pharyngitis and upper respiratory tract flora.

Authors:  P Christensen; B Hovelius; K Prellner; C Rosén; K K Christensen; D N Kurl; L Larsson; A Stjernquist-Desatnik; C Schalén
Journal:  Int Arch Allergy Appl Immunol       Date:  1985

5.  Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.

Authors:  Eugene V Millar; James P Watt; Melinda A Bronsdon; Jean Dallas; Raymond Reid; Mathuram Santosham; Katherine L O'Brien
Journal:  Clin Infect Dis       Date:  2008-10-15       Impact factor: 9.079

6.  Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine.

Authors:  F M Russell; A Balloch; M L K Tang; J R Carapetis; P Licciardi; J Nelson; A W J Jenney; L Tikoduadua; L Waqatakirewa; J Pryor; G B Byrnes; Y B Cheung; E K Mulholland
Journal:  Vaccine       Date:  2009-07-17       Impact factor: 3.641

7.  Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics.

Authors:  Markus A Rose; Matthias Gruendler; Ralf Schubert; Richard Kitz; Johannes Schulze; Stefan Zielen
Journal:  Vaccine       Date:  2009-07-02       Impact factor: 3.641

8.  Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.

Authors:  Stephen I Pelton; Heather Huot; Jonathan A Finkelstein; C J Bishop; Katherine K Hsu; Joan Kellenberg; Susan S Huang; Richard Goldstein; William P Hanage
Journal:  Pediatr Infect Dis J       Date:  2007-06       Impact factor: 2.129

Review 9.  Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates.

Authors:  Katherine L O'Brien; Lara J Wolfson; James P Watt; Emily Henkle; Maria Deloria-Knoll; Natalie McCall; Ellen Lee; Kim Mulholland; Orin S Levine; Thomas Cherian
Journal:  Lancet       Date:  2009-09-12       Impact factor: 79.321

Review 10.  Reconsideration of the use of meningococcal polysaccharide vaccine.

Authors:  Dan M Granoff; Andrew J Pollard
Journal:  Pediatr Infect Dis J       Date:  2007-08       Impact factor: 2.129
View more
  16 in total

1.  Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster.

Authors:  F M Russell; J R Carapetis; C Satzke; L Tikoduadua; L Waqatakirewa; R Chandra; A Seduadua; S Oftadeh; Y B Cheung; G L Gilbert; E K Mulholland
Journal:  Clin Vaccine Immunol       Date:  2010-10-13

2.  Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses.

Authors:  Paul V Licciardi; Anne Balloch; Fiona M Russell; Robert L Burton; Jisheng Lin; Moon H Nahm; Edward K Mulholland; Mimi L K Tang
Journal:  J Allergy Clin Immunol       Date:  2012-02-02       Impact factor: 10.793

3.  Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.

Authors:  F M Russell; J R Carapetis; R L Burton; J Lin; P V Licciardi; A Balloch; L Tikoduadua; L Waqatakirewa; Y B Cheung; M L K Tang; M H Nahm; E K Mulholland
Journal:  Vaccine       Date:  2010-10-31       Impact factor: 3.641

4.  Pneumococcal glycoconjugate vaccines produce antibody responses that strongly correlate with function.

Authors:  Paul V Licciardi; Anne Balloch; Fiona M Russell; Moon H Nahm; Kim Mulholland; Mimi L K Tang
Journal:  Nat Rev Drug Discov       Date:  2011-05       Impact factor: 84.694

5.  Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.

Authors:  F M Russell; A Balloch; P V Licciardi; J R Carapetis; L Tikoduadua; L Waqatakirewa; Y B Cheung; E K Mulholland; M L K Tang
Journal:  Vaccine       Date:  2011-05-01       Impact factor: 3.641

6.  Effect of pneumococcal vaccination on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus in Fijian children.

Authors:  Eileen M Dunne; Jayne Manning; Fiona M Russell; Roy M Robins-Browne; E Kim Mulholland; Catherine Satzke
Journal:  J Clin Microbiol       Date:  2011-12-14       Impact factor: 5.948

7.  No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.

Authors:  Paul V Licciardi; Zheng Quan Toh; Elizabeth A Clutterbuck; Anne Balloch; Rachel A Marimla; Leena Tikkanen; Karen E Lamb; Kathryn J Bright; Uraia Rabuatoka; Lisi Tikoduadua; Laura K Boelsen; Eileen M Dunne; Catherine Satzke; Yin Bun Cheung; Andrew J Pollard; Fiona M Russell; Edward K Mulholland
Journal:  J Allergy Clin Immunol       Date:  2016-01-26       Impact factor: 10.793

8.  Routine infant immunization with the 7- and 13-valent pneumococcal conjugate vaccines: current perspective on reduced-dosage regimens.

Authors:  Teresa Jackowska; Justyna Pluta
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

9.  Safety and immunogenicity of neonatal pneumococcal conjugate vaccination in Papua New Guinean children: a randomised controlled trial.

Authors:  William S Pomat; Anita H J van den Biggelaar; Suparat Phuanukoonnon; Jacinta Francis; Peter Jacoby; Peter M Siba; Michael P Alpers; John C Reeder; Patrick G Holt; Peter C Richmond; Deborah Lehmann
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

10.  Pneumococcal polysaccharide abrogates conjugate-induced germinal center reaction and depletes antibody secreting cell pool, causing hyporesponsiveness.

Authors:  Stefania P Bjarnarson; Hreinn Benonisson; Giuseppe Del Giudice; Ingileif Jonsdottir
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.